Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Further trial for Anika's Orthovisc underway in US:

This article was originally published in Clinica

Executive Summary

Anika Therapeutics has begun a further a Phase III clinical trial of its treatment for osteoarthritic knees, under an investigational device exemption from the US FDA. The Woburn, Massachusetts-based company failed to win US approval for the product last year due to insufficient data from its initial study. Orthovisc, an injectable hyaluronic acid-based product for restoring the elasticity and viscosity of synovial fluid, will be evaluated in around 350 patients at 20 sites in both Canada and the US.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT078336

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel